Supplementary Data File for "A Randomized, Double-blind, Phase III Study Assessing Clinical Similarity of SB17 (Proposed Ustekinumab Biosimilar) to Reference Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis"
Published: 19 April 2024| Version 1 | DOI: 10.17632/bh6p4rk5j9.1
Contributors:
, Joanna Narbutt, Giampiero Girolomoni, Jan Brzezicki, Nataliya Reznichenko, Maria Agnieszka Zegadlo-Mylik, Grazyna Pulka, Magdalena Dmowska-Stecewicz, Elżbieta Kłujszo, Dmytro Rekalov, Lidia Rajzer, , , Description
Supplementary Materials for the Paper "A Randomized, Double-blind, Phase III Study Assessing Clinical Similarity of SB17 (Proposed Ustekinumab Biosimilar) to Reference Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis" that is published in the Journal of the American Academy of Dermatology (JAAD).
Files
Categories
Psoriasis, Randomized Clinical Trial, Therapeutic Equivalence, Monoclonal Antibody Therapy
Funding
Samsung Bioepis Co., Ltd